An absence of galactose on the N-linked oligosaccharides of immunoglobulin G (IgG) has been shown to affect the functional activity of the antibody molecule. In patients with rheumatoid arthritis there is an increased proportion of IgG which lacks galactose and correspondingly lower levels of β1,4-galactosyltransferase (β4Gal-T) activity. The recent demonstration of several expressed β4Gal-T genes in man raises the possibility that the enzyme responsible for the decreased IgG galactose is not the "classical" β4Gal-T (β4Gal-T1). To directly address the question of whether reduced β4Gal-T1 would lead to reduced IgG galactose, the level of β4Gal-T1 in a human IgG-secreting B cell line was specifically altered using stable transfection with sense (SpcDNA3-Gal-T1) or antisense (ASpcDNA3-Gal-T1) human β4Gal-T1 cDNA. SpcDNA3-Gal-T1 B cell transfectants expressed up to a 2.5-fold higher level of β4Gal-T enzyme activity for the exogenous neoglycoconjugate acceptor GlcNAc-pITC-BSA than did ASpcDNA3-Gal-T1 transfectants. Flow cytometric analysis with Ricinus communis agglutinin I (RCAI) revealed an overall greater number of Galβ1,4GlcNAc structures in the fixed and permeabilized SpcDNA3-Gal-T1 B cell transfectants compared with the ASpcDNA3-Gal-T1 transfectants. Moreover, there was increased galactosylation of IgG secreted from the SpcDNA3-Gal-T1 transfectants relative to the ASpcDNA3-Gal-T1 B cell transfectants. Alteration of the level of the "classical" β4Gal-T (β4Gal-T1) in B cells therefore affects IgG glycosylation.
Introduction β1,4-galactosyltransferase (β4Gal-T) is located in the trans Golgi of most mammalian cells where it galactosylates GlcNAc residues on de novo synthesized glycoproteins. This process can generate oligosaccharide structures which are either fully galactosylated or only partially galactosylated. At Asn 297 in IgG there is a conserved N-linked glycosylation site which possesses a complex-type oligosaccharide chain. It is known that B lymphocyte clones secrete a number of IgG glycoforms having variable levels of galactose on this oligosaccharide. Hypogalactosylation of IgG has been shown to affect some of the effector functions of the IgG molecule including binding to complement component C1q (Tsuchiya et al., 1989; Wright and Morrison, 1998) , mannose-binding protein (Malhotra et al., 1995; Wright and Morrison, 1998) , and, in some studies, FcγR (Tsuchiya et al., 1989; Cant et al., 1994; Kumpel et al., 1994) , although the particular effects observed depend upon the details of the analysis. It is currently unclear if the biological effects of IgG hypogalactosylation are a direct result of the absence of galactose or a secondary effect on the protein conformation within the Fcγ2 region. Recently, it has been suggested that the orientation of the N-glycan chain on IgG affects its ability to activate complement (White et al., 1997) .
Patients with rheumatoid arthritis (RA) have a higher frequency of IgG lacking galactose (referred to as IgG G0) when compared to age-matched controls (Parekh et al., 1988) . This glycoform, which has terminal GlcNAc residues, was found to be more pathogenic than its galactosylated counterpart in an animal model of arthritis . The production of IgG G0 is a presecretory event (Bodman et al., 1992) and reduced β4Gal-T activity has been reported in the B cells from patients with RA (Axford et al., 1987; Furukawa et al., 1990; Wilson et al., 1993) . However, it has been questioned whether differences in β4Gal-T levels affect the number of G0 structures on human IgG because three separate B cell lines with different endogenous β4Gal-T activities were found to secrete IgG bearing similar amounts of galactose (Kumpel et al., 1994) . Furthermore, it has very recently become apparent that β4Gal-T activity is not mediated by a single enzyme, but that there are at least six functional β4Gal-T genes in man (Almeida et al., 1997; Lo et al., 1998; Sato et al., 1998a) . These enzymes are now designated β4Gal-T1 for the "classical" β4Gal-T, and β4Gal-T2 to β4Gal-T6 for the recently cloned transferases. The fine substrate specificity of each of these enzymes has yet to be fully analyzed, but it is clear that they do not all function in exactly the same way. For example, while β4Gal-T1 and β4Gal-T2 exhibit lactose synthetase activity in the presence of α-lactalbumin, β4Gal-T3 and β4Gal-T4 do not (Almeida et al., 1997; Sato et al., 1998a,b) .
In order to determine if the β4Gal-T1 member of the β4Gal-T family can utilize the oligosaccharides attached to the IgG polypeptide as an acceptor substrate, and to determine if it is possible to purposefully alter the glycosylation of IgG produced by a single B cell line, we have transfected B cells with vectors expressing sense or antisense human β4Gal-T1 cDNA. The resulting transfectants, with different β4Gal-T activities, were cultured and the secreted IgG assayed for terminal galactose.
Results

B cell β4Gal-T1 transfectants express Golgi-associated but not cell surface enzyme
The anti-human β4Gal-T mAb UCLgt1E7 (Keusch et al., unpublished observations) was used to identify β4Gal-T in the Downloaded from https://academic.oup.com/glycob/article-abstract/8/12/1207/597680 by guest on 10 August 2018 Fig. 1 . Flow cytometric analysis of (a) nonpermeabilized and (b) fixed and permeabilized B cell transfectants, SpcDNA3-Gal-T1 (bold line) and ASpcDNA3-Gal-T1 (thin line) stained with anti-β4Gal-T mAb UCLgt1E7 followed by rabbit F(ab′) 2 anti-mouse IgG-FITC. The dotted line represents cells incubated with a negative isotype control MOPC-21 followed by rabbit F(ab′) 2 anti-mouse IgG-FITC. transfected B cells. β4Gal-T was only detected in B cell transfectants which had been fixed and permeabilized and not on the cell surface (Figure 1) . B cells transfected with sense β4Gal-T1 cDNA (SpcDNA3-Gal-T1) contained higher levels of β4Gal-T than those cells transfected with antisense β4Gal-T1 cDNA (ASpcDNA3-Gal-T1) (Figure 1b) . The intracellular staining was confirmed as predominantly localized to the Golgi using confocal microscopy. Thus, the transfection procedure and subsequent expression of the β4Gal-T protein resulted in appropriate compartmentalization for this enzyme's role in the biosynthesis of glycoconjugates.
Quantification of intracellular and secreted β4Gal-T protein
The SpcDNA3-Gal-T1 B cell transfectants expressed approximately 5.5-fold more cell-associated β4Gal-T protein (24.9 ± 2.25 ng/mg total protein) compared to the ASpcDNA3-Gal-T1 transfectants (4.0 ± 0.75 ng/mg total protein, p < 0.001, unpaired Student's t-test; Figure 2a ). This enhanced β4Gal-T expression was also apparent in the secreted fraction (7.5 ± 0.5 ng/10 6 viable cells compared to 1.5 ± 0.4 ng/10 6 viable cells) (Figure 2b ). 
β4Gal-T enzyme activity is decreased in the antisense transfectants
The cell lysates from SpcDNA3-Gal-T1 B cell transfectants had a maximum 2.5-fold higher level of β4Gal-T enzyme activity relative to those from the ASpcDNA3-Gal-T1 B cell transfectants (p < 0.001) using the exogenous acceptor substrate GlcNAcpITC-BSA ( Figure 3 ). Similar data were obtained following 16 days and 19 days of culture. Over the three time points there was an average 34% increase and 39% decrease in β4Gal-T activity, for sense and antisense, respectively, compared to B cells transfected with control pcDNA3 plasmid, i.e., the endogenous B cell β4Gal-T activity level.
The galactosylation of B cell substrates is altered
An increase in the number of endogenous cell-associated Galβ1,4GlcNAc structures was observed in SpcDNA3-Gal-T1 relative to the ASpcDNA3-Gal-T1 B cell transfectants ( Figure 4) . A major secretory glycoprotein produced by this B cell line is IgG1. Whilst some IgG antibodies are known to possess N-linked glycosylation in their variable regions, the JAC-10 antibody bears only Fc-associated oligosaccharides due to the absence of consensus sequences for N-linked glycosylation in both the heavy and light chain variable regions (Bye et al., 1992) . The secreted IgG1 was purified from SpcDNA3-Gal-T1 and ASpcDNA3-Gal-T1 B cell culture supernatants (which lacked any other gamma globulins) and analyzed for the presence of terminal galactose residues. The IgG secreted from the SpcDNA3-Gal-T1 transfectants contained an average of 18% Fc-associated G0 whereas that secreted from the ASpcDNA3-Gal-T1 transfectants had much higher levels of IgG lacking galactose, i.e., an average of 45% G0 ( Figure 5 ).
Discussion
The particular glycoforms borne by proteins can profoundly influence their function (Wright and Morrison, 1997) . It is therefore important to understand the mechanisms by which glycosylation is controlled, the regulation of these processes, and to develop strategies by which the glycosylation of a protein can be tailored in a very highly specific manner.
In order to examine the relationship between the level of β4Gal-T1 and galactosylation, we modified β4Gal-T1 expression in an IgG-secreting human B cell line. Alterations in the level of galactose on IgG are known to affect the biological properties of this molecule. Our approach was to specifically alter the level of the glycosyltransferase by stable transfection with vectors expressing β4Gal-T1 in either the sense or the antisense orientations. A similar approach was used by Zeng and colleagues using antisense oligonucleotides for GM2-and GD3-synthase to modify glycolipid synthesis in HL60 cells (Zeng et al., 1995) . Other approaches that have been used to alter protein glycosylation include treatment of the glycoprotein with individual exoglycosidases (Katoh et al., 1995) , alteration of cell culture conditions (Kumpel et al., 1994) , the use of transgenic (Prieto et al., 1995) and knockout (Asano et al., 1997; Lu et al., 1997) animals, and the use of Lec mutants of CHO cells in which individual glycosyltransferases are absent or overexpressed (Stanley et al., 1996) .
In our experiments we found that a 2.5-fold difference in β4Gal-T activity between the SpcDNA3-Gal-T1 and ASpcDNA3-Gal-T1 B cell transfectants resulted in different levels of galactosylation of cell-associated endogeneous B cell substrates. Furthermore, there was a substantial difference in Fc-associated IgG G0 structures between the transfectants. In other studies increasing the β4Gal-T activity 3-fold in F9 cells by transfection with the β4Gal-T1 gene did not result in any changes in lysosomal-associated membrane protein-1 (LAMP-1) galactosylation (Youakim and Shur, 1993) . This difference between the two proteins could be due to different substrate preferences of β4Gal-T1 in relation to other β4Gal-T enzymes, and/or to the internal nature of the Fc-associated oligosaccharides on IgG. Culturing the F9 cells at 20_C, thereby increasing the transit time of glycoproteins through the Golgi, did enhance both the number and extent of polylactoaminoglycans attached to LAMP-1 and -2 (Wang et al., 1991) .
Long and short forms of β4Gal-T1 are produced by the use of alternative initiation codons (Russo et al., 1990) . In the ASpcDNA3-Gal-T1 transfectants only the endogenous B cell β4Gal-T is present (at a reduced level), whereas in the SpcDNA3-Gal-T1 transfectants there will additionally be overexpression of the full-length β4Gal-T1 cDNA. The ratio of cellular to secreted β4Gal-T protein remained relatively constant irrespective of the β4Gal-T activity level in the B cell transfectants. β4Gal-T along with a number of other Golgi proteins can occur as dimers (Bendiak et al., 1993; Fleischer et al., 1993) . A dimer of ST6Gal I which accounted for a third of the total enzyme in the Golgi of HeLa cells was found to be catalytically inactive, but could still bind its acceptor substrate (Ma and Colley, 1996) . If Golgi-associated β4Gal-T consists of a mixture of monomers, dimers, and higher order oligomers, then the increased or decreased expression of β4Gal-T1 may influence structural and functional aspects of the enzyme, and would explain the lack of a directly quantitative association between enzyme protein levels and enzyme activity. Modulation of β4Gal-T activity might also occur through posttranslational modifications such as phosphorylation (Bunnell et al., 1990) .
The binding of the anti-β4Gal-T mAb to fixed and permeabilized B cells resulted in characteristic Golgi staining, the normal cellular location of β4Gal-T. However, with the monoclonal antibody used (UCLgt1E7), cell surface β4Gal-T was not detected, even after transfection with the β4Gal-T1 cDNA in the sense orientation. Low but measurable cell surface β4Gal-T has been reported on another EBV-transformed B cell line, JY (Mrkoci-Felner et al., 1997) . This difference might be due either to inherent differences between the two cell lines, or related to different expression of β4Gal-T epitopes recognized by different monoclonal antibodies. However, a greater than 12-fold expression of GalT1 activity in COS-7 cells transfected with SpcDNA3-GalT1, resulted in detection of the enzyme at the cell surface using the UCLgt1E7 mAb (data not shown).
Decreased levels of galactose on IgG are associated with certain rheumatological disorders. Lower β4Gal-T enzyme levels have been described in these diseases although the actual β4Gal-T enzyme(s) involved has yet to be established. While the Fc-associated oligosaccharides are not usually fully galactosylated, those in the Fab usually are (Rademacher et al., 1996) . This suggests that the relative inaccessibility of the Fc-associated sugars which are enclosed within the Cγ2 domains plays a role in the regulation of galactosylation. Reduced β4Gal-T enzyme activity could be due to an alteration in a β4Gal-T (misfolding or posttranslational modification) which causes the enzyme to inefficiently galactosylate IgG or the enzyme may be fully functional but produced at a lower level. We show here that a reduction in the level of enzyme comparable to that seen in some patients with RA is sufficient to cause an increase in Fc-associated IgG G0. Although we have been unable to detect a direct relationship between B cell β4Gal-T1 mRNA levels and IgG hypogalactosylation in patients with RA (Jeddi et al., 1996) , it would be of interest to determine if β4Gal-T gene transfection into the B cells from patients with RA is able to correct the glycosylation of their IgG. This would not be straightforward, however, due to the fact that EBV transformation itself has been reported to upregulate β4Gal-T activity in lymphocytes isolated from patients with RA, and therefore they no longer reflect the natural in vivo situation with respect to increased IgG G0 (Wilson et al., 1993) . The use of freshly isolated patients' B cells would also be problematic due to the necessity to maintain untransformed B cells in long term culture during the selection of transfectants. Although this can be achieved by culturing B cells in the presence of CD40L and appropriate cytokines (Rousset et al., 1995) , the effect of such procedures on protein glycosylation are currently unknown.
Materials and methods β4Gal-T1 antisense/sense vector constructs
The full-length β4Gal-T1 cDNA from clone CT7-J20 (Masri et al., 1988) was excised out of Bluescript KS and subcloned into the eukaryotic expression vector pcDNA3, under the control of the CMV promoter, in the sense (BamHI/XhoI digests, SpcDNA3-Gal-T1) and the antisense (HindIII/BamHI digests, ASpcDNA3-Gal-T1) directions. Ligation and correct orientation of the β4Gal-T1 inserts into the vector was verified using differential restriction enzyme digests and DNA sequencing of the 5′ insert end using the Sequenase v2.0 DNA sequencing kit according to the manufacturer's instructions (United States Biochemical).
B cell transfection with β4Gal-T1 constructs
The JAC-10 EBV-transformed human B cell line (Kumpel et al., 1994) was cultured in RPMI-1640 with 25 mM HEPES and sodium bicarbonate and supplemented with 10% heat-inactivated fetal bovine serum (<0.1 µg/ml IgG, Life Technologies, Paisley, UK), 2 mM glutamine, 50 IU penicillin, and 50 µg/ml streptomycin ("complete medium"). Prior to transfection, B cells were washed free of antibiotics using Hanks' balanced salt solution, then resuspended at 4 × 10 6 cells/ml in complete medium (without antibiotics). Cells were distributed at 500 µl /well into 24 well tissue culture plates. Three micrograms of PEG-precipitated DNA at 1 mg/ml was added to 100 µl of RPMI and mixed gently with 100 µl of Lipofectin (Life Technologies, Paisley, UK) at 100 µg/ml in RPMI for 15 min at room temperature (Cumin et al., 1993) . The DNA-Lipofectin complexes were added to the cells and incubated at 37_C in 5% CO 2 for 8 h. The cells were then washed and resuspended in fresh complete medium at 0.5 × 10 6 cells/ml and recultured. Forty-eight hours later cells were washed and resuspended in complete medium containing 800 µg/ml G418 (Santerre et al., 1984) (pretitrated against untransfected cells to determine the effective lethal dose). The cells were then continuously cultured in G418-containing complete medium, with resuspension at 0.5 × 10 6 cells/ml every 72 h in fresh medium. After 6 weeks of selection, aliquots of the transfectants were frozen down and stored in liquid nitrogen. All the data reported were obtained following recovery of the cells from storage and subsequent culture for 7 days (except where stated otherwise) of the transfectants in complete medium with G418. Cells were lysed and assayed for β4Gal-T enzyme activity and protein, and culture supernatants (containing secreted IgG and secreted β4Gal-T) were collected and stored in aliquots at -20_C prior to analysis.
β4Gal-T enzyme activity
After reculturing the transfectants for 7 days, β4Gal-T activity was measured using GlcNAc-pITC-BSA as the acceptor substrate in an ELISA-based assay as described previously (Keusch et al., 1995) .
β4Gal-T protein quantification
Cellular and secreted β4Gal-T protein was measured in the B cell lysates and culture supernatants, respectively, using a sandwich ELISA which proved highly reproducible and sensitive down to 1 ng/ml (50 pg per well) of β4Gal-T protein (Keusch et al., unpublished observations) . In this assay Maxisorp ELISA plates were coated overnight at 4_C with 50 µl/well of streptavidin at 5 µg/ml in 0.15 M phosphate-buffered saline pH7.4 (PBS), and blocked with 100 µl of PBS-1% BSA. After washing, half of the plate was incubated with 50 µl/well of biotinylated isotype control MOPC-21 IgG1 at 5 µg/ml in PBS while the other half was incubated with a synergistic pair of biotinylated anti-human β4Gal-T mAbs UCLgt1B6 and UCLgt1H11, each at 2.5 µg/ml in PBS, for 2 h at 37_C and then overnight at 4_C. Following washing, the plates were incubated with 50 µl/well of purified human milk β4Gal-T standards at doubling dilutions from 60 ng/ml, or with 50 µl of test sample. All assay points were carried out in duplicates on both sides of the plates. Plates were incubated for 2 h at 37_C, then washed and incubated with 50 µl of a previously described affinity-purified rabbit anti-human β4Gal-T (Watzele et al., 1991) at 5 µg/ml in PBS-Tween 20 0.05% (PBS-T)-1% BSA for 1 h at 37_C. After washing, plates were incubated with 50 µl/well of goat F(ab′) 2 anti-rabbit IgG-horseradish peroxidase (Jackson ImmunoResearch Laboratories, West Grove, PA) at 1:2000 in PBS-T-1% BSA for 1 h at 37_C. Plates were washed and developed using 50 µl/well of 1 mg/ml o-phenylenediamine in 0.1 M citrate phosphate buffer, pH 5.0 with 0.03% H 2 O 2 . The reaction was stopped with 100 µl/well of 3N H 2 SO 4 and the absorbances read at 490 nm using a Dynatech MR5000 ELISA plate reader.
Immunofluorescence staining of B cell transfectants
Aliquots of 2.5 × 10 5 cells were washed in PBS and the cell pellets each resuspended in 100 µl of a fully characterized murine IgG1 anti-human β4Gal-T mAb UCLgtIE7 (Keusch et al., unpublished observations) or IgG1 isotype control mAb MOPC-21 at 20 µg/ml in buffer (PBS-1% BSA with 15 mM NaN 3 ), and incubated for 45 min at 4_C. Following two 1 ml washes, 50 µl of rabbit F(ab") 2 anti-mouse IgG-FITC (Dako, Buckinghamshire, UK), diluted 1:10 in buffer was used to resuspend the cell pellet and incubated for 45 min at 4_C in the dark. Cells were washed twice in PBS and resuspended in 250 µl PBS. For intracellular staining, 1 × 10 6 cells were fixed and permeabilized by resuspension in 500 µl of working strength PermeaFix reagent (Ortho Diagnostic Systems, Buckinghamshire, UK) followed by a 40 min incubation at 20_C in the dark and two washes in 1 ml of buffer. The staining procedure was as described above except that an additional 30 min wash step was included following the incubation with the primary antibody. For the detection of exposed galactose, 100 µl of biotinylated Ricinus communis agglutinin I (RCAI; Vector Laboratories, Peterborough, UK) at 0.08 µg/ml in buffer was added to PermeaFixed cells and incubated as above. Cells were washed and 50 µl of 1:100 streptavidin-FITC (Serotec, Oxford, UK) added and incubated for 45 minutes at 4_C. Following washing, a minimum of 5000 stained cells were assessed using a Becton Dickinson FACScan.
IgG galactosylation ELLA
This enzyme-linked lectin assay was performed as previously described (Sumar et al., 1990) on supernatants obtained following 3 days of reculture of the transfectants. The standards used contained known amounts of IgG G0, determined by the Department of Biochemistry, University of Oxford, using the hydrazinolysis method. A standard curve of the absorbance ratios at 410 nm of Bandeiraea simplicifolia II (BSII)/RCAI against known amounts of IgG G0 was plotted and the sample absorbances interpolated.
